These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37921680)

  • 21. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
    Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA
    Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
    McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
    Am Surg; 2024 Aug; 90(8):2078-2079. PubMed ID: 38553440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
    Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
    J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
    Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
    JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
    Long GV; Lipson EJ; Hodi FS; Ascierto PA; Larkin J; Lao C; Grob JJ; Ejzykowicz F; Moshyk A; Garcia-Horton V; Zhou ZY; Xin Y; Palaia J; McDonald L; Keidel S; Salvatore A; Patel D; Sakkal LA; Tawbi H; Schadendorf D
    J Clin Oncol; 2024 Aug; ():JCO2401125. PubMed ID: 39137386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Namba Y; Yamazaki N
    J Dermatol; 2020 Nov; 47(11):1257-1266. PubMed ID: 32812243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
    Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
    Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
    Thudium K; Selby M; Zorn JA; Rak G; Wang XT; Bunch RT; Hogan JM; Strop P; Korman AJ
    Cancer Immunol Res; 2022 Oct; 10(10):1175-1189. PubMed ID: 35981087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
    N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
    Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
    Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
    [No Abstract]   [Full Text] [Related]  

  • 32. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Tsuchida T; Yoshida A; Yamada T; Komoto A
    J Dermatol; 2023 Sep; 50(9):1108-1120. PubMed ID: 37350027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
    Dimitriou F; Hauschild A; Mehnert JM; Long GV
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis.
    Zhu Y; Cheng H; Zhong M; Hu Y; Li Q; Gao X; Liu S
    J Cancer Res Ther; 2021 Dec; 17(7):1679-1688. PubMed ID: 35381739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.